Cantex Pharma 
Welcome,         Profile    Billing    Logout  
 2 Products   45 Diseases   2 Products   8 Trials   255 News 


123»
  • ||||||||||  Herceptin (trastuzumab) / Roche, azeliragon (TTP488) / Cantex Pharma, Perjeta (pertuzumab) / Roche
    RAGE inhibition to decrease cancer therapy related cardiotoxicity in women with early breast cancer (RAGE). (Hall A; Poster Bd #: 207a) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1347;    
    P1/2
    In Cohort 4, 6 patients will receive dose dense doxorubicin and cyclophosphamide (ddAC)...As of 2/1/24, 4 patients have been enrolled, with 4 undergoing screening. At the completion of this trial, we plan a randomized trial to evaluate the role of TTP488 to decrease cardiotoxicity, cancer related cognitive decline and disease recurrence.
  • ||||||||||  dociparstat sodium (CX-01) / Cantex Pharma, Chimerix
    Trial termination, Combination therapy:  Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (clinicaltrials.gov) -  Apr 15, 2024   
    P3,  N=9, Terminated, 
    At the completion of this trial, we plan a randomized trial to evaluate the role of TTP488 to decrease cardiotoxicity, cancer related cognitive decline and disease recurrence. Active, not recruiting --> Terminated; Study enrollment was terminated on 16 May 2022 due to slow recruitment.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Journal:  Macrophage RAGE activation is proinflammatory in NASH. (Pubmed Central) -  Jan 4, 2024   
    FFC mice that received a pharmacological inhibitor of RAGE (TTP488), and myeloid-specific RAGE KO mice (RAGE-MKO) had attenuated liver injury associated with a reduced accumulation of RAGE+ recruited macrophages...Correspondingly, the secretome of ligand-stimulated bone marrow derived macrophages from RAGE-MKO mice had an attenuated capacity to activate CD8+ T cells. Our data implicate RAGE as what we propose to be a novel and potentially targetable mediator of the proinflammatory signaling of recruited macrophages in NASH.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Enrollment open:  Azeliragon in MGMT Unmethylated Glioblastoma (clinicaltrials.gov) -  Oct 27, 2023   
    P2,  N=30, Recruiting, 
    TTP488 could potentially be an alternative to dexamethasone in the perioperative management of patients undergoing tumor resection or other neurosurgical interventions. Not yet recruiting --> Recruiting
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Enrollment open, Trial initiation date:  Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  Sep 15, 2023   
    P1/2,  N=18, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Mar 2023 --> Sep 2023
  • ||||||||||  dociparstat sodium (CX-01) / Cantex Pharma, Chimerix
    Journal:  Platform-agnostic electrochemical sensing app and companion potentiostat. (Pubmed Central) -  Aug 25, 2023   
    The versatility of PocketEC, developed with an assay developer mindset, was demonstrated by interfacing it, via Bluetooth, to the ADuCM355 evaluation board, the open-source DStat potentiostat and the Voyager board, a custom-built, small footprint potentiostat based around the LMP91000 chip...Importantly, the versatility of the app makes it a candidate of choice for the development of future portable potentiostats. Finally, the app is available to download on the Google Play store and the source codes and design files for the PocketEC app and the Voyager board are shared via Creative Commons license (CC BY-NC 3.0) to promote the development of novel portable or wearable applications based on electrochemical sensing.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    New P2 trial:  Azeliragon in MGMT Unmethylated Glioblastoma (clinicaltrials.gov) -  Aug 14, 2023   
    P2,  N=30, Not yet recruiting, 
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Journal:  RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer. (Pubmed Central) -  Jul 14, 2023   
    These results show that TTP488 impairs metastasis of TNBC and further clarifies the signaling and cellular mechanisms through which RAGE mediates metastasis. Importantly, as TTP488 displays a favorable safety profile in human studies, our study provides the rationale for evaluating TTP488 in clinical trials to treat or prevent metastatic TNBC.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Review, Journal:  RAGE Inhibitors in Neurodegenerative Diseases. (Pubmed Central) -  May 16, 2023   
    Some of the RAGE antagonists, such as Azeliragon, are currently in clinical development for treating neurological diseases, including AD, although currently there have been no FDA-approved therapeutics based on the RAGE antagonists. This review outlines the AGE-RAGE interactions as a leading cause of the onset of neurological diseases and the current efforts on developing therapeutics for neurological diseases based on the RAGE antagonists.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    RAGE EXPRESSING MACROPHAGE SUBSETS MEDIATE INFLAMMATION IN NASH (South Hall A, Poster Hall - McCormick Place) -  Mar 23, 2023 - Abstract #DDW2023DDW_1520;    
    FFC-RLMC-KO and RAGE-i mice had significant attenuation of liver injury compared to FFC-WT and vehicle treated controls respectively, assessed by NAS-grading and ALT. Further, RLMC-KO mice had significantly lower RAGE expression by IHC of liver sections and fibrosis compared to FFC fed WT-mice.
  • ||||||||||  azeliragon (TTP488) / Cantex Pharma
    Trial initiation date:  Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  Mar 10, 2023   
    P1/2,  N=18, Not yet recruiting, 
    Further, RLMC-KO mice had significantly lower RAGE expression by IHC of liver sections and fibrosis compared to FFC fed WT-mice. Initiation date: Dec 2022 --> Mar 2023
  • ||||||||||  Enrollment open, Trial completion date, Trial primary completion date:  RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (clinicaltrials.gov) -  Jan 9, 2023   
    P1/2,  N=48, Recruiting, 
    Initiation date: Dec 2022 --> Mar 2023 Not yet recruiting --> Recruiting | Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
  • ||||||||||  Trial initiation date, Metastases:  RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (clinicaltrials.gov) -  Sep 29, 2022   
    P1/2,  N=48, Not yet recruiting, 
    Importantly, as TTP488 displays a high safety profile in human trials, this study provides the rationale for evaluating TTP488 in clinical trials to treat or prevent metastatic breast cancer. Initiation date: Aug 2022 --> Nov 2022
  • ||||||||||  dociparstat sodium (CX-01) / Chimerix
    Journal:  WHITE-COAT HYPERTENSION WITHOUT ORGAN DAMAGE: IMPACT OF LONG-TERM MORTALITY, NEW HYPERTENSION AND NEW ORGAN DAMAGE. (Pubmed Central) -  Aug 27, 2022   
    Our study may also indicate that 6-O-desulfated heparin, as an excellent heparin derivative, is a potential therapeutic agent for myocardial I/R injury. The present study provides the first evidence that WCH with no cardiac and renal OD is accompanied by an increased long-term risk of mortality, new hypertension and new OD, thereby not representing a clinically innocent condition.
  • ||||||||||  dociparstat sodium (CX-01) / Chimerix
    Journal:  Forecasting Bitcoin Price Using Interval Graph and ANN Model: A Novel Approach. (Pubmed Central) -  Aug 9, 2022   
    The empirical study has clearly demonstrated the encouraging performance and effectiveness of the IG-ANN. The performance is compared with traditional ANN techniques on bitcoin time-series data spanning 2013-2019 and found that IG-ANN is outperforming all.
  • ||||||||||  dociparstat sodium (CX-01) / Cantex Pharma, Chimerix
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy:  Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (clinicaltrials.gov) -  Jun 16, 2022   
    P3,  N=9, Active, not recruiting, 
    The performance is compared with traditional ANN techniques on bitcoin time-series data spanning 2013-2019 and found that IG-ANN is outperforming all. Recruiting --> Active, not recruiting | N=570 --> 9 | Trial completion date: Feb 2026 --> Dec 2022 | Trial primary completion date: May 2024 --> Dec 2022
  • ||||||||||  Trial initiation date, Metastases:  RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (clinicaltrials.gov) -  Jun 14, 2022   
    P1/2,  N=48, Not yet recruiting, 
    Recruiting --> Active, not recruiting | N=570 --> 9 | Trial completion date: Feb 2026 --> Dec 2022 | Trial primary completion date: May 2024 --> Dec 2022 Initiation date: May 2022 --> Aug 2022
  • ||||||||||  dociparstat sodium (CX-01) / Chimerix
    Preclinical, Journal:  Small molecule compound M12 reduces vascular permeability in obese mice via blocking endothelial TRPV4-Nox2 interaction. (Pubmed Central) -  Jun 8, 2022   
    Furthermore, we showed that interrupting TRPV4-Nox2 coupling by TRPV4 knockout, or by treatment with a specific Nox2 inhibitor Nox2 dstat or a specific TRPV4 inhibitor HC067046 significantly attenuated obesity-induced ROS overproduction in aortic endothelial cells, and reversed the abnormal endothelial cytoskeletal structure...TRPV4-Nox2 complex is a potential drug target in improving oxidative stress and disruption of the vascular barrier in obesity. Compound M12 targeting TRPV4-Nox2 complex can improve vascular barrier function in obesity.